Followers
0
Following
2
Blog Posts
0
Threads
16,715
Blogs
Threads
Portfolio
Follower
Following
2020-11-23 18:33 | Report Abuse
yes sad too.. how to getting out pn17? rili big problem..
2020-11-23 17:34 | Report Abuse
thanks de info bulldog.. Im also believe tat 2nd wave coming for real..
2020-11-23 17:00 | Report Abuse
pray for the best.. come come
2020-11-23 16:59 | Report Abuse
yalo.. last year I'm here. can said earn 4 times? aiya.. investment only..
2020-11-23 16:50 | Report Abuse
haha.. this year how calculate could tear give 0.30 cents. how trap high oh.. huhuhu...
2020-11-23 16:30 | Report Abuse
down buy buy, up buy buy, everywhere buy buy....
2020-11-23 16:30 | Report Abuse
ya how up without u buy.. aduh..
2020-11-23 16:14 | Report Abuse
OK OK... behind huat ah....
2020-11-23 15:13 | Report Abuse
yeah ur hope will come true..
2020-11-23 15:07 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 15:05 | Report Abuse
yes winner patient.. patient winner..
2020-11-23 14:40 | Report Abuse
big volume coming eating....
2020-11-23 14:34 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:27 | Report Abuse
good news for everyone.... up up
2020-11-23 14:24 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:21 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:20 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:20 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:19 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:19 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:18 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:18 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:17 | Report Abuse
let's 10000% work smoothly....
2020-11-23 14:15 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 14:14 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
2020-11-23 12:12 | Report Abuse
The price quoted was around RM 4000 per box, which contains 100 test kit. In conclusion, based on the above review, there was no evidence ...
Stock: [MTOUCHE]: MTOUCHE TECHNOLOGY BHD
2020-11-23 21:50 | Report Abuse
let's 10000% work smoothly..